PATRYS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.009 AUD | 0.00% |
|
+12.50% | +12.50% |
| 04-10 | Patrys Reports 'Positive' Results for Deoxymabs in Autoimmune Vasculitis Treatment | MT |
| 02-23 | Patrys Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 3.33M 2.19M 175M | Sales 2023 | 2.85M 1.88M 150M | Capitalization | 20.57M 13.55M 1.08B |
|---|---|---|---|---|---|
| Net income 2022 | -6M -3.95M -315M | Net income 2023 | -7M -4.61M -367M | EV / Sales 2022 | 9.39 x |
| Net cash position 2022 | 9.82M 6.47M 516M | Net cash position 2023 | 4.05M 2.66M 212M | EV / Sales 2023 | 5.8 x |
| P/E ratio 2022 |
-5.78
x | P/E ratio 2023 |
-2.91
x | Employees | 10 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.29% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +12.50% | ||
| 1 month | -5.26% | ||
| 3 months | +12.50% | ||
| 6 months | +12.50% | ||
| Current year | +12.50% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.01
1 year
0.010.02
3 years
0.010.06
5 years
0.010.06
10 years
0.000.08
| Managers | Title | Age | Since |
|---|---|---|---|
James Campbell
CEO | Chief Executive Officer | - | 11/11/14 |
| Chief Tech/Sci/R&D Officer | - | 31/05/12 | |
Rebecca Tunstall
PRN | Corporate Officer/Principal | - | 15/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pamela Klein
BRD | Director/Board Member | 63 | 30/09/19 |
James Campbell
CEO | Chief Executive Officer | - | 11/11/14 |
Michael Stork
BRD | Director/Board Member | - | 18/02/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.009 | 0.00% | 310 555 |
| 26/04/24 | 0.009 | 0.00% | 2,075,883 |
| 24/04/24 | 0.009 | 0.00% | 455,777 |
| 23/04/24 | 0.009 | +12.50% | 26,670 |
| 22/04/24 | 0.008 | -11.11% | 7,222 |
Delayed Quote Australian S.E., April 29, 2024 at 04:20 am
More quotes
Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.
Calendar
21/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +12.50% | 12.07M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PAB Stock
